Carisma Therapeutics, OrthoCellix enter definitive merger agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Merger Announcement: Carisma Therapeutics and OrthoCellix have entered into a definitive all-stock merger agreement, focusing on the development of OrthoCellix's NeoCart technology for treating knee cartilage defects, with plans to initiate a Phase 3 clinical trial by the end of 2025.
Ownership Structure and Future Plans: Following the merger, OrthoCellix stockholders are expected to own approximately 90% of the combined company, which will be renamed OrthoCellix, Inc., trading under the ticker 'OCLX,' with the transaction anticipated to close in the second half of 2025.
Analyst Views on OCGN
Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.620
Low
4.00
Averages
9.00
High
15.00
Current: 1.620
Low
4.00
Averages
9.00
High
15.00
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
